You have 9 free searches left this month | for more free features.

BRCA2

Showing 1 - 25 of 861

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Breast Cancer, Genetic Disease, BRCA2 Mutation Trial (blood sample for BRCA2 mutation detection)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • blood sample for BRCA2 mutation detection
  • (no location specified)
Jun 1, 2023

Germline Variant Carriers With BRCA1 or BRCA2

Recruiting
  • BRCA1 and/or BRCA2 Variant Carriers
  • +3 more
    • Okayama, Japan
      Okayama University
    Dec 25, 2022

    BRCA1/2 Flu Vaccine

    Active, not recruiting
    • BRCA1 Mutation
    • BRCA2 Mutation
    • Seasonal influenza vaccine
    • Philadelphia, Pennsylvania
      University of Pennsylvania
    Aug 16, 2022

    BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)

    Active, not recruiting
    • BRCA1 Gene Mutation
    • +5 more
    • Durvalumab
    • +3 more
    • Buffalo, New York
    • +1 more
    Jan 20, 2023

    BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer Trial in Providence (Talazoparib Oral Capsule)

    Active, not recruiting
    • BRCA1 Mutation
    • +4 more
    • Talazoparib Oral Capsule
    • Providence, Rhode Island
    • +1 more
    Nov 30, 2022

    Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation Trial in San Francisco (Niraparib, Irinotecan)

    Not yet recruiting
    • Metastatic Solid Tumor
    • +4 more
    • San Francisco, California
      University of California, San Francisco
    Jan 12, 2023

    Endocrine Disruptors and Life STILe in Breast Cancer Development

    Recruiting
    • Breast Cancer
    • +5 more
      • Roma, Italy
        Alessandra Fabi
      Feb 25, 2023

      Breast Cancer Trial in New York (core needle biopsy, blood draw)

      Recruiting
      • Breast Cancer
      • core needle biopsy
      • blood draw
      • New York, New York
        Memorial Sloan Kettering Cancer Center (All Protocol Activities)
      Nov 9, 2023

      Breast Cancer, Metastatic Breast Cancer, BRCA1 Gene Mutation Trial in Boston (ABT-888, temozolomide)

      Active, not recruiting
      • Breast Cancer
      • +3 more
      • Boston, Massachusetts
      • +2 more
      Dec 21, 2022

      Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by

      Completed
      • Breast Cancer
      • Blood test
      • Questionnaire
      • New York, New York
        Memorial Sloan Kettering Cancer Center
      Dec 27, 2021

      Triple Negative Breast Tumors, Triple Negative Breast Cancer, Breast Tumors Trial (Pembrolizumab, Paclitaxel, Carboplatin)

      Not yet recruiting
      • Triple Negative Breast Neoplasms
      • +7 more
      • (no location specified)
      Aug 1, 2022

      Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation Trial (Olaparib, LHRH agonist)

      Not yet recruiting
      • Prostate Cancer
      • +4 more
      • (no location specified)
      Aug 10, 2022

      Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8 Trial (Biospecimen Collection,

      Not yet recruiting
      • Prostate Adenocarcinoma
      • +2 more
      • Biospecimen Collection
      • +6 more
      • (no location specified)
      Mar 28, 2023

      Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation Trial in Boston, New York (Melphalan, BCNU, Vitamin B12B)

      Recruiting
      • Pancreatic Adenocarcinoma Metastatic
      • +14 more
      • Boston, Massachusetts
      • +1 more
      Dec 6, 2022

      Ultra-rapid BRCA1/2 Status Screening Test in Theranostic

      Not yet recruiting
      • Breast Cancer
      • Questionnaires
      • Communication of the results of the BRCA1/2 ultra rapid test
      • (no location specified)
      Oct 26, 2023

      Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer Trial in Stanford (Talazoparib Tosylate)

      Active, not recruiting
      • Advanced Breast Cancer
      • +2 more
      • Talazoparib Tosylate
      • Stanford, California
        Stanford University Hospitals and Clinics
      Nov 16, 2022

      Searching for Novel Germline Mutations in Lobular Breast Cancer

      Recruiting
      • Lobular Breast Carcinoma
      • +3 more
      • Illumina panel
      • Milan, Italy
        European Institute of Oncology
      Sep 12, 2022

      BRCA1 Mutation, BRCA2 Mutation Trial in New York, Durham, Houston (Family Letter (Standard of Care), Educational Video, Mailed

      Recruiting
      • BRCA1 Mutation
      • BRCA2 Mutation
      • Family Letter (Standard of Care)
      • +3 more
      • New York, New York
      • +2 more
      Aug 12, 2022

      l, Laboratory and Epidemiologic Characterization of Individuals

      Completed
      • Familial Ovarian Cancer
      • +3 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Dec 31, 2022

        Identification of a Genetic Predisposition to ProstAte Cancer

        Active, not recruiting
        • Prostate Cancer in BRCA1 and BRCA2 Carriers
        • PSA test
        • Prostate Biopsy
        • Sutton, Surrey, United Kingdom
          Cancer Genetics Unit, Royal Marsden Hospital
        Mar 30, 2022

        BRCA1/2 Mutation Trial in Philadelphia (INO-5401, INO-9012, Cellectra 2000)

        Recruiting
        • BRCA1/2 Mutation
        • Philadelphia, Pennsylvania
          University of Pennsylvania
        Dec 7, 2021

        Molecular Profiling in Prostate Cancer

        Recruiting
        • Prostate Cancer Metastatic
        • +4 more
        • Tumor molecular profiling
        • Athens, Greece
          Hellenic Cooperative Oncology Group
        Mar 15, 2022

        TNBC - Triple-Negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation Trial (olaparib, Durvalumab)

        Not yet recruiting
        • TNBC - Triple-Negative Breast Cancer
        • +2 more
        • (no location specified)
        Jan 12, 2022

        Ovarian Tumors, BRCA1 Protein, BRCA2 Protein Trial in Worldwide (KU-0059436 (AZD2281)(PARP inhibitor))

        Active, not recruiting
        • Ovarian Neoplasms
        • +2 more
        • KU-0059436 (AZD2281)(PARP inhibitor)
        • Brussels, Belgium
        • +4 more
        Dec 19, 2022